Kaisa Group Holdings has entered an agreement to purchase 18.57% stake in Zhenxing Biopharmaceutical & Chemical.

Based in China, the acquirer company is involved in property investment, development, and management businesses. It aims to expand its footprint in the healthcare industry through the acquisition.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“Zhongyuan Union Cell & Gene Engineering, formerly Zhongyuan Union Stem Cell Bioengineering, plans to divest 67% share in a pharmaceutical tech company headquartered in Zhejiang.”

The purchase consideration for the acquisition is agreed to be $331.65m.

Zhongyuan Union Cell & Gene Engineering, formerly Zhongyuan Union Stem Cell Bioengineering, plans to divest 67% share in a pharmaceutical tech company headquartered in Zhejiang.

The divestment is expected to generate CNY60m ($9.1m) in proceeds for Zhongyuan.

Zhongyuan Union Stem Cell Bioengineering is a biotechnology company based in China.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact